Investors & Media Press Releases

Press Releases

Summary Toggle

01.13.2020

Summary Toggle Axovant Announces Positive 12-month Data on AXO-Lenti-PD and Provides Updates Across Gene Therapy Pipeline Programs

Summary ToggleNEW YORK and BASEL, Switzerland, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced recent progress in its gene therapy programs, including a 12-month update on its
Read More

PDF Version
Read More
Summary Toggle

12.19.2019

Summary Toggle Axovant Provides Clinical Program Update for AXO-AAV-GM1, a Novel Investigational Gene Therapy for GM1 Gangliosidosis

Summary ToggleNEW YORK and BASEL, Switzerland , Dec. 19, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT) today announced preliminary findings from an expanded access treatment in which a single patient with GM1 gangliosidosis was administered investigational AXO-AAV-GM1 gene therapy.
Read More

PDF Version
Read More
Summary Toggle

12.03.2019

Summary Toggle Axovant Announces Amendment to Credit Facility with Hercules Capital

Summary ToggleNEW YORK and BASEL, Switzerland , Dec. 03, 2019 (GLOBE NEWSWIRE) -- New loan amendment reduces loan obligation by 50% without penalty, eliminates minimum cash covenant, and extends interest-only period for 9 months Debt service burden reduced by approximately $2.0 million per month during
Read More

PDF Version
Read More
Summary Toggle

11.18.2019

Summary Toggle Axovant Gene Therapies Receives Orphan Drug Designation from FDA for AXO-AAV-GM1 for the Treatment of GM1 Gangliosidosis

Summary ToggleNEW YORK and BASEL, Switzerland , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug Administration ( FDA ) has granted orphan drug designation for the Company’s
Read More

PDF Version
Read More
Summary Toggle

11.08.2019

Summary Toggle Axovant Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2019

Summary ToggleFirst evidence of clinical stabilization in two children with Tay-Sachs disease that received AXO-AAV-GM2 presented at ESGCT in October 2019 Continued enrollment of patients in AXO-AAV-GM1 registrational study, with 6-month data from Part A of the registrational study expected in mid-2020 3-month
Read More

PDF Version
Read More
Summary Toggle

11.05.2019

Summary Toggle Axovant Gene Therapies Announces Investor Conference Presentations for the Remainder of 2019

Summary ToggleNEW YORK and BASEL, Switzerland , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu, M.D., chief executive officer, will present at the following investor conferences: 10
Read More

PDF Version
Read More
Summary Toggle

10.23.2019

Summary Toggle Axovant Presents First Evidence of Clinical Stabilization in Tay-Sachs Disease at the European Society of Gene and Cell Therapy 27th Annual Congress

Summary ToggleInitial data with AXO-AAV-GM2 suggests stabilization of disease course, attainment of normal developmental milestones, and improvement in myelination on brain MRI AXO-AAV-GM2 generally safe and well-tolerated to date Additional data to be presented by Dr.
Read More

PDF Version
Read More
Summary Toggle

10.10.2019

Summary Toggle Axovant Gene Therapies Announces Upcoming Presentations at the European Society of Gene and Cell Therapy 27th Annual Congress

Summary ToggleNEW YORK and BASEL, Switzerland , Oct. 10, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced upcoming presentations regarding its investigational gene therapy programs, AXO-Lenti-PD, AXO-AAV-GM1 and
Read More

PDF Version
Read More
Summary Toggle

09.25.2019

Summary Toggle Axovant Gene Therapies to Present at 2019 Cell & Gene Meeting on the Mesa

Summary ToggleBASEL, Switzerland , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Parag Meswani , Pharm.D., senior vice president, commercial strategy & operations, will present at the annual Cell
Read More

PDF Version
Read More
Summary Toggle

08.09.2019

Summary Toggle Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2019

Summary ToggleSUNRISE-PD Phase 2 trial of AXO-LENTI-PD for Parkinson's disease continues to enroll patients in second dose cohort with data expected in the fourth quarter of calendar 2019 Data from patients dosed with AXO-AAV-GM1 and AXO-AAV-GM2 expected in fourth quarter of calendar 2019 Net loss for the
Read More

PDF Version
Read More

Investors & Media Press Releases

Press Releases

Email Alerts

Print

Email

Search

Investors & Media Press Releases

Press Releases

Toolbar

Email Alerts

Print

Email

Search